跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT07315659
NCT07315659招募中不适用

Time-Restricted Eating as a Potential Strategy to Promote Weight Loss Maintenance in Patients With Obesity (REGANE)

Universidad de Granada1 个研究点 分布在 1 个国家目标入组 212 人开始时间: 2025年12月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
212
试验地点
1
主要终点
Change in weight (Kg) during the 6 months following the end of the calorie restriction intervention
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

While body weight reduction can be achieved through various interventions in people living with obesity, most patients regain a substantial proportion of the lost weight within the following months. There is a lack of effective interventions to prevent this regain, making weight regain one of the most pressing challenges in obesity management. The goal of this clinical trial is to determine whether adhering to time-restricted eating (TRE; a form of intermittent fasting) during and after a dietary weight loss intervention, promotes weight maintenance to a greater extent than consuming all daily meals within 11 hours or more. Additionally, the study will address other questions, such as whether TRE improves body composition, insulin sensitivity, and cardiometabolic risk factors; whether the TRE intervention produces effects on different components of energy balance or related behaviors; and whether prior exposure to the TRE intervention influences eating window duration and weight change over the subsequent 24 months.

The study will compare participants who concentrate all their food intake within 8 hours or less with those who consume all their daily meals within 11 hours or more. All participants will follow a calorie-restricted diet designed to induce an 8-10% weight loss over 12-16 weeks and will be followed for several months after the weight loss intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Have a body mass index of 30-45 kg/m
  • •Have safety laboratory test results (general biochemistry and complete blood count) within the normal reference range or with abnormalities considered clinically insignificant by the medical research team and that do not require the initiation of drug treatment.
  • •Have sufficient venous access for the blood sampling required by the procedures described in this protocol, and not have a phobia of needles or blood.
  • •Maintain a usual intake window of 11 hours or longer at least 5 days a week and have a response rate greater than 85% during the self-recording carried out during the screening process.
  • •Willingness and ability to consume all foods provided during the outcome assessment and dietary intervention.
  • •Being able to understand and undergo the procedures that are part of the study, in the opinion of the research team.
  • •Availability to participate in the study.
  • •Be willing to complete the study regardless of the group to which they are assigned.

排除标准

  • •Having received a diagnosis or presenting signs or symptoms that, in the opinion of the research team, could contraindicate TRE intervention or any of the procedures included in the study.
  • •Having been diagnosed with or having a history of metabolic (including a diagnosis of any type of diabetes mellitus), hematological, pulmonary, cardiovascular, gastrointestinal, neurological, immune, hepatic, renal, urological or psychiatric diseases that could interfere with the study results or compliance with the protocol.
  • •Having undergone any surgical procedure that, in the opinion of the research team, could alter energy metabolism or digestive function during the course of the study.
  • •Taking drugs or supplements that are likely to alter body weight or appetite.
  • •Have experienced weight loss of more than 10% in the last two years, or more than 5% in the last 6 months, unless all the weight lost has been regained.
  • •Follow unconventional eating patterns, such as vegan or fasting diets, or be unable to tolerate the foods provided during the study.
  • •Being pregnant or planning to become pregnant within the next two years.
  • •Being in the postpartum phase (within 12 months of giving birth) or breastfeeding.
  • •Being in the perimenopausal stage, defined as meeting the criteria of irregular menstrual cycles, hormonal changes indicative of perimenopause, or the presence of menopausal symptoms.
  • •Participating in a nutritional intervention or treatment or having done so during the previous 3 months.
  • •Having been diagnosed with or showing signs or risk factors for the development of an eating disorder.
  • •Experiencing frequent interruptions in the sleep-wake cycle.
  • •Having clinically significant gastric emptying abnormalities, a current diagnosis of any form of diabetes, blood pressure greater than 160/90 mm Hg, or heart rate below 50 or above 100 beats per minute (sitting), with or without stable doses of antihypertensive medication.
  • •Have an active or untreated malignant disease or be in remission from a clinically significant malignant disease for less than five years prior to the time of evaluation.
  • •Having a history of drug or alcohol abuse or testing positive for drugs, unless due to medication prescribed by a healthcare professional.
  • •Smoking, vaping, or regular use of tobacco products, unless there have been periods of at least 24 consecutive hours without consumption during the last 4 weeks.
  • •Regular consumption of caffeine in excess of the equivalent of 3 espressos per day (225 mg/day).
  • •Being a direct relative or cohabitant of research team personnel.
  • •Any other condition that, in the opinion of the research team, makes participation in the study inadvisable.

研究组 & 干预措施

Time-restricted eating (eating within 8 hours/day or less)

Experimental

Participants in the time-restricted eating group will be instructed to concentrate all daily meals to 8 hours or less

干预措施: Calorie restriction (Dietary intervention) (Behavioral)

Time-restricted eating (eating within 8 hours/day or less)

Experimental

Participants in the time-restricted eating group will be instructed to concentrate all daily meals to 8 hours or less

干预措施: Time-restricted eating (Behavioral)

结局指标

主要结局

Change in weight (Kg) during the 6 months following the end of the calorie restriction intervention

时间窗: 6 after the end of the dietary intervention - End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss).

次要结局

  • Weight (Kg)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention)
  • Waist circumference (cm)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Hip Circumference (cm)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Body Mass Index (kg/m2)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum HDL cholesterol (mg/dl)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum glucose (mg/dl)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum insulin (U/ml)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum hemoglobin A1c (mmol/mol)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fat mass (kg) by DXA(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fat free mass (kg) by DXA(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fat mass (kg) by Bioimpendaciometry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fat free mass (kg) by Bioimpendaciometry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Resting Energy Expenditure (kcal/day) measured by indirect calorimetry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fasting nutrient utilization rates (g/min) measured by indirect calorimetry and protein excretion(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Posprandial Energy Expenditure (kcal/day) measured by indirect calorimetry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Maximal fat oxidation (g/min) by indirect calorimetry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Sedentary time (min/day) measured by accelerometry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention)
  • Serum LDL cholesterol (mg/dl)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum triglycerides (mg/dl)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum Alanine Transaminase (U/L)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention)
  • Postprandial nutrient utilization rates (g/min) measured by indirect calorimetry and protein excretion(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Energy Intake (kcal) in an Ad-Libitum Meal Test(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Physical activity (counts/day) measured by accelerometry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 after the end of dietary intervention.)
  • Energy efficiency (W/KJ) while cycling, assessed by indirect calorimetry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Habitual food consumption collected by a food frecuency questionnaire(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Serum Total Cholesterol (mg/dl)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum C-reactive protein (mg/dL)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Craving Control measured using the Control of Eating Weekly Questionnaire (CoEQ)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum thyrotropin (µU/mL)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Positive Mood measured using the Control of Eating Weekly Questionnaire (CoEQ)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Craving for Sweet Foods measured using the Control of Eating Weekly Questionnaire (CoEQ)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Craving for Savory Foods measured using the Control of Eating Weekly Questionnaire (CoEQ)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fasting appetite-related sensations measured using "Visual Analogue Scales (VAS)"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Meal-induced changes in appetite-related sensations measured using "Visual Analogue Scales (VAS)" in response to a meal(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Serum Aspartate Transaminase (U/L)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Serum gamma-glutamyl transferase (U/L)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fasting Liking and Wanting measured using Leeds Food Preference Questionnaire(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Liking and Wanting in response to a meal measured using Leeds Food Preference Questionnaire(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Meal-induced changes in serum glucose concentration (mg/dL) in response to a standardized meal(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Meal-induced changes in serum insulin concentration (U/ml) in response to a standardized meal(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Cognitive restriction of food intake measured using the "Three-Factor Eating Questionnaire"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Food disinhibition measured using the "Three-Factor Eating Questionnaire"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Subjective hunger measured using the "Three-Factor Eating Questionnaire"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Binge eating behavior measured using the "Binge Eating Questionnaire"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Sleep time (min) measured by accelerometry(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Handgrip strength (kg) measured using a dynamometer(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Functional mobility measured by "Timed Up and Go (TUG)" test(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Walking speed (m/s) measured by a gait speed test(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Independence in activities of daily living (ADL) measured by "Barthel Index"(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention)
  • Food cravings measured using the "Food Craving Inventory" questionnaire(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention)
  • Carbohydrate intake (g/day) collected through three 24-hour recalls(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fat intake (g/day) collected through three 24-hour recalls(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Protein intake (g/day) collected through three 24-hour recalls(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Fiber intake (g/day) collected through three 24-hour recalls(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Changes in appetite-related sensations measured using "Visual Analogue Scales (VAS)" in response to a submaximal stress test(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 6 months after the end of dietary intervention.)
  • Resting heart rate variability(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Resting Systolic blood pressure (mmHg)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)
  • Resting Diastolic blood pressure (mmHg)(Baseline; End of dietary intervention (Week 12/16, depending on achievement of 8-10% weight loss); 1, 3, 6, 12, 18, 24 and 36 months after the end of dietary intervention.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Guillermo Sanchez Delgado

Ramon y Cajal Researcher (Tenure-track position)

Universidad de Granada

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME TrialType 2 Diabetes
NCT07272460Mount Sinai Hospital, Canada112
招募中
不适用
Intervention of time restricted eating on obese adults with fatty liver: Pilot study
KCT0005390Korea Association of Health Promotion105
已完成
不适用
Is Time Restricted Eating (TRE) a practical way to help people lose weight?Nutritional, Metabolic, EndocrineObesity
ISRCTN16400313Queen Mary University of London50
招募中
2 期
Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
2024-518402-40-00Ente Ospedaliero Ospedali Galliera Di Genova90
进行中（未招募）
不适用
Time Restricted Eating Plus Exercise for Weight ManagementIntermittent FastingCognitive DeclinePre Diabetes
NCT05290233University of Illinois at Chicago40
Time-Restricted Eating as a Potential Strategy to... | 临床试验